Matinas BioPharma Holdings, Inc. - MTNB STOCK NEWS

Matinas BioPharma Holdings (NYSE AMER: MTNB) has initiated a Phase 1 study of MAT2501, an oral formulation of amikacin, with the first patient dosed. The trial aims to assess safety, tolerability, and pharmacokinetics, completing enrollment by Q1 2022 and reporting data in Q2 2022. MAT2501 targets nontuberculous mycobacterial infections and marks a significant advancement as a potential first oral aminoglycoside. Supported by a $4.2 million award from the Cystic Fibrosis Foundation, MAT2501 has received FDA designations that could provide up to 12 years of marketing exclusivity if approved.

Matinas BioPharma Holdings, Inc. (NYSE: MTNB) announced the nomination of Kathryn Penkus Corzo for election to its Board of Directors at the 2021 Annual Meeting on November 1, 2021. Corzo, a partner at Takeda Ventures and former Head of Oncology Cell Therapy Development at Takeda, brings over 25 years of experience in biopharma. The company also noted that Patrick LePore will not seek re-election. Notable advancements include positive EnACT data for MAT2203, showing 95% survival in HIV patients with cryptococcal meningitis.

Matinas BioPharma (MTNB) presented its company overview at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation is available on-demand via their investor website. Matinas focuses on the intracellular delivery of therapeutics using its lipid nanocrystal (LNC) platform. Their lead product, MAT2203, an oral formulation of amphotericin B, shows promising Phase 2 results in HIV patients with cryptococcal meningitis. Additionally, MAT2501 is set to enter Phase 1 trials for treating bacterial infections.

Matinas BioPharma (MTNB) announced positive results from the EnACT trial of MAT2203 for treating cryptococcal meningitis. Early Fungicidal Activity (EFA) reached 0.38 log₁₀ CFU/mL/day, surpassing the target of >0.20, indicating effective fungal clearance. A 95% overall survival rate was observed in Cohort 2 with no breakthrough infections. MAT2203 showed no kidney toxicity or electrolyte issues during 6 weeks of treatment. The Data Safety Monitoring Board supports advancing to Cohort 3, with enrollment underway, and the company plans to seek FDA engagement for early approval.

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB) announced a Notice of Allowance from the USPTO for its oral formulation MAT2203, an antifungal medicine. This patent, covering a combination of amphotericin B and additional antifungal agents for treating central nervous system infections, extends patent protection to 2037. The company now holds six issued U.S. patents and 25 patents for its lipid nanocrystal platform, enhancing MAT2203's commercial potential. MAT2203 is currently in a Phase 2 clinical trial for cryptococcal meningitis in HIV patients, with further studies expected.

Matinas BioPharma Holdings, Inc. (MTNB) announced the completion of patient enrollment in the second cohort of the EnACT study for MAT2203, targeting cryptococcal meningitis, with data review expected in September 2021. Positive FDA feedback has enabled the initiation of a Phase 1 study for MAT2501, anticipated in Q4 2021. In vitro studies of lipid nanocrystal formulations of remdesivir show enhanced efficacy compared to traditional forms. Financially, cash reserves stood at approximately $59.8 million, providing operational support into 2024, with a reduced net loss of $5 million in Q2 2021.

Matinas BioPharma (MTNB) announced CEO Jerome D. Jabbour will participate in the BTIG Virtual Biotechnology Conference on August 10, 2021, at 3:00 p.m. ET. The company will also hold investor meetings during this event. Matinas focuses on enhancing drug delivery through its lipid nanocrystal (LNC) technology, which aims to overcome complex delivery challenges for therapeutics. Their lead candidates include MAT2203, an oral antifungal for cryptococcal meningitis, and MAT2501, an oral antibiotic for bacterial infections, both nearing significant clinical milestones.

Matinas BioPharma (NYSE: MTNB) announced a conference call on August 10, 2021, at 8:00 a.m. ET to discuss Q2 2021 operational and financial results. The call can be accessed by dialing (877) 407-5976 or through the company's website. Matinas is focused on enhancing drug delivery through its lipid nanocrystal (LNC) technology, with key products in development, including MAT2203 for cryptococcal meningitis and MAT2501 for bacterial infections. The company aims to address significant challenges in intracellular drug delivery, showing promise in various therapeutic areas.

Matinas BioPharma (MTNB) has announced a virtual R&D Day on June 17, 2021, at 8:30 a.m. ET, highlighting its lipid nanocrystal (LNC) delivery platform and pipeline programs. Key leaders, including Professors David Boulware and Peter Pappas, will provide clinical insights. The company is developing products like MAT2203 for cryptococcal meningitis and MAT2501 for nontuberculous mycobacterial lung infections, backed by funding from the Cystic Fibrosis Foundation. LYPDISO™ shows promising results in triglyceride management against Vascepa. A live Q&A session will follow the presentations.